Beyond K-Pop: How Korean Innovation Can Shape the Future of Global Health

Session
Partners

Session Summary

Important
Quotations

“Most people think that TB is just a disease of the past. But still, as you mentioned, it’s the global top killer.”
Dr. Han-oh Park
“I believe at that moment AI could unleash hidden information from this data... and predict earlier, detect earlier... and predict future risk factors.”
Dr. Sang Joon Park
“We really want to raise awareness and understanding of the Korean innovation ecosystem... how they can potentially transform the way healthcare services are accessed and delivered not only in high-income countries but also high-burden countries.”
Jaqueline Huh

Key
Takeaways

  • Korean health innovators are much less known globally than brands like Samsung and Hyundai. The session aimed to raise awareness of Korea’s health innovation companies and products, and of their potential to change how care is delivered in high-burden countries. 
  • Bioneer, Korea’s first biotech company (founded in 1992), grew out of government investment in genetic engineering and early work on DNA synthesis and PCR. It has developed diagnostic tests for every major outbreak since SARS. During COVID-19, when U.S. exports of testing instruments were restricted, its testing instruments reached more than 90 countries. 
  • TB remains the world’s top infectious killer, causing more deaths than HIV and malaria combined, yet it is a hard market because the countries hit hardest have the smallest budgets. Dr. Han-Oh Park’s commitment is personal: after the Korean War, TB devastated a poor and crowded Korea, and the country still has one of the highest TB rates among OECD nations. 
  • Drug-resistant TB is the biggest threat because it can’t be treated with standard drugs. Bioneer’s point-of-care test detects resistance to four drugs in about 40 minutes and is in international trials toward WHO prequalification, with support from FIND, the RIGHT Foundation, the Korean government, and the Gates Foundation. 
  • Medical IP began from the observation that hospitals use only a small fraction of the imaging data they generate. Its AI, trained on CT scans, can extract 3D-like information from a single chest X-ray, a major advantage in low-resource settings where CT scanners are scarce. 
  • Losing his father to pneumonia in 2020 led Dr. Sang Joon Park to move from cancer and heart disease to COVID-19 pneumonia and then to TB. The same health technology can serve both infectious and chronic diseases. 
  • The Stop TB Partnership has worked with Medical IP on AI for more than a decade, weighing the risks as well as the benefits long before AI became a mainstream topic. 

Action
Items

  • Connect Korean health innovators with global health buyers, funders, and national TB programs in high-burden countries so promising products become visible and available. 
  • Funders and partners should continue backing validation trials and WHO prequalification so new diagnostics reach patients faster. 
  • Expand rapid point-of-care testing for drug-resistant TB so patients get the right treatment early and resistance spreads less. 
  • Deploy AI chest X-ray tools in low-resource settings to get more diagnostic value from equipment health systems already have. 
  • Design health technologies that screen for several conditions at once, such as TB, pneumonia, and lung cancer, to make better use of limited resources. 
  • Build governance for health AI that weighs its risks alongside its benefits, drawing on early adopters like the Stop TB Partnership.